Piper Jaffray Downgrades Vitae Pharmaceuticals (VTAE) to Neutral
- Techs buoy S&P, Nasdaq; Goldman pushes Dow to record high
- Buy Any Seasonal Market Weakness Ahead of Year End Rally - Oppenheimer (SPY)
- Oil hits 16-month high in buying rush after OPEC agreement
- Consolidated Communications (CNSL) to Acquire FairPoint Communications (FRP) in $1.5B Deal
- Berkshire Hathaway (BRK-A) Book Value Could Be Boosted by $29B from Trump Tax Plan - Analyst
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Piper Jaffray downgraded Vitae Pharmaceuticals (NASDAQ: VTAE) from Overweight to Neutral.
Shares of Vitae Pharmaceuticals closed at $20.85 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Goldman Sachs Downgrades Marvell (MRVL) to Sell
- Morgan Stanley Downgrades Arista Networks (ANET) to Equalweight
- Citi Downgrades Kinross Gold (KGC) to Sell
Create E-mail Alert Related CategoriesDowngrades
Related EntitiesPiper Jaffray
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!